POLE and endometrial carcinoma: Recently published 2023 FIGO guidelines also recommended performing molecular classification in all endometrial carcinomas if possible, specially in stages I and II, where in case of harboring pathogenic mutations on POLE, clinical prognosis remains excellent, and therefore these cases should be downstaged to a IAm.